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hCDC4 (FBW7, FBXW7) is a new potential tumor suppressor gene which provides substrate specificity for SCF 
(Skp–Cullin–F-box) ubiquitin ligases and thereby regulates the degradation of potent oncogenes such as cyclin E, 
Myc, c-Jun and Notch. Mutations in the hCDC4 gene have been found in several solid tumors such as pancreas, 
colorectal or endometrial cancer. We carried out a mutation analysis of the hCDC4 gene in 35 samples of patients 
with Acute Myeloid Leukemia (AML) to elucidate a possible role of hCDC4 mutations in this disease. By direct 
DNA sequencing and digestion with Surveyor nuclease one heterozygous mutation in the 5’ untranslated region 
of exon 1, transcript variant 3 was detected. Additionally, we could identify a new intronic SNP downstream of 
exon 10. The new variation was present in 20% of AML samples and was furthermore confirmed in a panel of 51 
healthy individuals where it displayed a frequency of 14%. In conclusion we provide first data that in contrast to 
several solid tumors, mutations in the hCDC4 gene may not play a pivotal role in the pathogenesis of AML. 
Furthermore, we describe a new intronic polymorphism with high frequency in the intron sequence of the 
hCDC4 gene.  
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1.  Introduction 
The F-box and WD40 domain protein 7 (hCDC4, 
FBW7, FBXW7) has recently emerged as a potent new 
potential tumor suppressor gene [1, 2]. The highly 
conserved protein consists of an NH2 terminal F-box 
and seven WD40 repeats in the COOH terminal region 
and acts as an adaptor protein providing substrate 
specificity for SCF (Skp–Cullin–F-box) ubiquitin 
ligases which are involved in tagging proteins for 
degradation in the proteasome. 
hCDC4 has been shown to target specifically 
cyclin E [3], Myc [4], c-Jun [5] and Notch [6] for 
proteasomal degradation and therefore negatively 
regulates several key oncoproteins.  
Mutations in the CDC4 gene have been detected 
in several solid tumors such as colorectal cancer [7, 8], 
endometrial cancer [9, 10] or cell lines [11]. Further-
more, defective hCDC4 may be involved in cellular 
pathways leading to chromosomal instability [12]. 
As the disruption of the above described cellular 
oncogenic pathways also plays an important role in 
hematological malignancies we were interested 
whether mutations of hCDC4 can also be observed in 
Acute Myeloid Leukemia (AML) or high risk 
Myelodysplastic Syndrome (MDS). Therefore we 
carried out a mutational analysis of the hCDC4 gene in 
35 samples of AML patients in order to elucidate 
whether hCDC4 mutations may be relevant for the 
genesis of this disease. 
2.  Materials and Methods 
Nucleic acid preparation 
Heparinized bone marrow (BM) samples from 22 
and peripheral blood (PB) samples from 13 Patients 
with AML were obtained at the time of their initial 
diagnosis after informed consent. For control, 51 PB 
samples were obtained from voluntary healthy 
individuals after informed consent. Mononuclear cells 
were separated by density gradient centrifugation 
through Ficoll-Hypaque (Biochrom, Berlin, Germany). 
Genomic DNA (gDNA) was extracted from 
mononuclear cells using TRIZOL reagent (Invitrogen, 
Life Technologies, Grand Island, NY) according to the 
manufacturer’s protocol. The content of gDNA was 
adjusted to 30 ng/μl for further analyses. 
Polymerase chain reaction 
The common exons 2 to 11 and the three known 
variants of exon 1 of the hCDC4 gene (Figure 1A) were 
amplified by polymerase chain reaction (PCR). Primers 
were synthesized by Metabion International AG 
(Martinsried, Germany). Reaction conditions were as 
follows: An initial denaturation step at 95°C for 15 
minutes was followed by 35 cycles consisting of 
denaturation at 95°C for 30 seconds (s), annealing at 
58°C for 30s and elongation at 72°C for 60s followed by 
a final elongation step at 72°C for 7 min.   
Primer sequences can be supplied upon request. 
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electrophoresis on a 2% agarose gel and subsequently 
purified with the QIAquick PCR purification system 
(QIAGEN, Hilden, Germany). 
Figure 1. (A) Overview depicting the common exons 2 – 11 and the three transcript variants (TV) of exon 1 of the hCDC4 
gene. Arrows mark the position of the detected mutation in the 5’ UTR of Exon 1-TV3 and the new intronic SNP 
downstream of exon 10. (B) Chromatograph of the mutation detected in exon 1. (C-E) Chromatographs of the different 
variations of the new intronic SNP in the hCDC4 gene on chromosome 4, position 153602874. (F) Gel electrophoresis of a 
Surveyor nuclease digested PCR product of the AML sample containing the mutation in exon 1 versus digestion of the 
reference sequence (Ref. Seq.) (negative control). (G) Gel electrophoresis of surveyor nuclease digested PCR products of 
wild type samples containing the newly identified C/T SNP versus the reference sequence (Ref. Seq.) and samples lacking 
the SNP. 
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Direct DNA sequencing and mutational analysis 
Purified PCR products were sequenced at the 
DLMBC sequencing service (Dr. M. Meixner) in the 
Department of Biochemistry of the Charité, Berlin, 
Germany using the ABI PRISM Big Dye Terminator 
system (Applied Biosystems, Germany). Sequences 
were analyzed using the Chromas software (Technely-
sium Pty Ltd, Tewantin, Australia) and GeneDoc 
software (http://www.psc.edu/biomed/genedoc). 
Sequences were analyzed in alignment with the NCBI 
and ENSEMBLE reference sequences of hCDC4: 
ENST00000281708 / NM_033632, ENST00000263981 / 
NM_018315, ENST00000296555 / NM_001013415. 
Sequences with deviations were re-amplified and 
re-sequenced for confirmation. 
Surveyor nuclease digestion 
Exon 1 (transcript variant 3) and exon 10 were 
amplified from selected samples with PCR parameters 
as described above. After a control electrophoresis on 
2% agarose gels, the PCR products were directly 
subjected to processing with Surveyor nuclease [13] 
(Transgenomic, Omaha, USA) according to the 
protocol supplied by the manufacturer: PCR products 
from a reference sequence were mixed at equimolar 
amounts with wild type samples, denatured at 95°C 
for 2 minutes and subsequently re-hybridized. In case 
of sequence deviations in the wildtype samples from 
the reference sequence this resulted in the formation of 
heteroduplexes containing mismatches. In the 
following incubation with Surveyor nuclease for 20 
min. at 42°C heteroduplexes were cleaved at mismatch 
sites by the enzyme leading to DNA fragments with 
reduced length. These digestion products were 
subjected to electrophoresis on 2% agarose gels.  
3.  Results 
Mutational analysis of hCDC4 in AML 
In this study the common exons 2 to 11 and the 
three known transcript variants of exon 1 of hCDC4 
(Figure 1A) were analyzed by direct DNA sequencing 
in 35 samples derived from bone marrow or peripheral 
blood of AML patients at the time point of initial 
diagnosis. This resulted in the identification of one 
heterozygous mutation in the 5’ untranslated region 
(5’UTR) of Exon 1 (transcript variant 3, NM_001013415) 
comprising a heterozygous T > C exchange of 
nucleotide (nt) 108 of the exon sequence (Figure 1B). 
Being located in an untranslated region of the exon, the 
mutation has no consequence for the hCDC4 protein. 
Sequence analysis of hCDC4 exon 10 identifies a new 
intronic SNP 
During the analysis of exon 10 and adjacent 
intronic sequences we could for the first time identify a 
new single nucleotide polymorphism (SNP) in the 
intron sequence flanking the 3’ end of exon 10 in 7 out 
of 35 (20%) patient samples. The SNP consisted of a C 
> T exchange (Figure 1 C-E) and was positioned at nt 
67 of the intron sequence (chromosome 4, position 
153602874).  
Because this variation had as yet not been 
classified as a known polymorphism we wanted to 
determine whether it could possibly be disease specific 
and therefore carried out a validation in 51 DNA 
samples of healthy individuals. This led to the 
confirmation of the SNP as it was also present in 7 out 
of 51 (13.7%) healthy individuals. The new C > T SNP 
was submitted to dbSNP (NCBI), identifier: NCBI_ss# 
P1_1 49855991. Genotype frequencies are summarized 
in Table 1. 
Table 1. Genotype and frequency of the newly identified 
SNP in the hCDC4 gene 
SNP C/T, Chromosome 4, Chromosome Pos. 153602874 
AML (n=35)  Healthy individuals (n=51) 
Genotype  n / (%)  Genotype  n / (%) 
C/C C/C 
C/T C/T 
T/T 
28 / (80) 
7 / (20) 
0 / (0)  T/T 
44 / (86) 
6 / (12) 
1 / (2) 
Confirmation of sequence deviations with surveyor 
nuclease 
In order to confirm the mutation found in exon 1 
(transcript variant 3) and the new SNP we subjected 
selected samples to a mismatch specific digestion 
procedure employing Surveyor nuclease.  
As depicted in Figure 1F the AML sample 
containing the mutation in exon 1 features cleavage 
products of approximately 284 bp and 173 bp size as 
compared to no detectable cleavage products in the 
reference sequence (negative control). These fragments 
corresponded to the lengths of the sequence 
surrounding the detected mutation in exon 1. Similarly, 
analysis of samples containing the C/T SNP 
downstream of exon 10 led to the identification of 
cleavage products of approximately 101 bp and 444 bp 
in size in samples either containing the heterozygous 
C/T or homozygous T/T SNP while these fragments 
could not be detected in samples lacking the SNP and 
therefore corresponded to the reference sequence 
(Figure 1 G).  
4.  Discussion 
The elucidation of the molecular pathogenesis of 
AML has led to the realisation that the emergence of 
this disease is linked with mutations and aberrations in 
numerous genes controlling transcription, 
proliferation and apoptosis [14]. The hCDC4 gene has 
recently been identified as a new potent tumor 
suppressor as it has been shown to be responsible for 
the specific degradation of central oncogenes such as 
c-Jun, Notch, cyclin E and c-myc [3-6]. As these 
oncogenes have all been demonstrated to play roles in 
AML and MDS [15-18] and the hCDC4 gene features 
mutations in several solid tumors [7-11], we wanted to 
examine whether hCDC4 might also be mutated in 
DNA samples of AML. 
As demonstrated here, direct sequencing of 35 
DNA samples derived from patients with AML 
revealed one heterozygous mutation in the 
untranslated region of transcript variant 3 of exon 1 in 
form of a T > C exchange. A mutation of the hCDC4 
gene at this location has not yet been described in Int. J. Med. Sci. 2006, 3 
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previous mutation analyses. In contrast to this silent 
mutation detected here, mutations discovered 
previously in solid tumors such as colon or pancreas 
cancer had the tendency to be accumulated in exons 4, 
8 and 9 and were of missense or nonsense type [7-11]. 
Therefore, the observation that only one heterozygous 
mutation with no consequence on the translated 
protein was found while screening 14 exons of 35 
patient samples suggests that mutations of hCDC4 do 
not play a significant role in the pathogenesis of AML.  
During sequence analysis of exon 10 in the AML 
samples we identified a new intronic SNP which we 
subsequently confirmed by sequencing DNA samples 
of 51 healthy individuals. Interestingly, this SNP had 
not yet been registered in any SNP databases despite 
of its high frequency of 20% in samples of patients with 
AML and 13,7% in healthy individuals. After its 
confirmation by re-sequencing and digestion of 
selected samples with mismatch specific Surveyor 
nuclease we therefore submitted the new variation to 
dbSNP (NCBI). The difference of genotype frequency 
between AML patients and healthy individuals is not 
significant (p=0.31) and therefore most probably not 
disease specific. 
In conclusion we provide first data that mutations 
of the hCDC4 gene may not play a pivotal role in the 
pathogenesis of AML. This supplements studies which 
have discovered hCDC4 mutations in subsets of solid 
tumors and implies that mutations of hCDC4 are 
restricted to certain tumor types. Furthermore, we 
describe a new SNP with high frequency in the hCDC4 
gene on chromosome 4, position 153602874. 
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